Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adenoviruses are potent vectors for inducing and boosting cellular immunity to encoded recombinant antigens. However, the widespread seroprevalence of neutralizing antibodies to common human adenovirus serotypes limits their use. Simian adenoviruses do not suffer from the same drawbacks. We have constructed a replication-deficient chimpanzee adenovirus-vectored vaccine expressing the conserved influenza antigens, nucleoprotein (NP), and matrix protein 1 (M1). Here, we report safety and T-cell immunogenicity following vaccination with this novel recombinant simian adenovirus, ChAdOx1 NP+M1, in a first in human dose-escalation study using a 3+3 study design, followed by boosting with modified vaccinia virus Ankara expressing the same antigens in some volunteers. We demonstrate ChAdOx1 NP+M1 to be safe and immunogenic. ChAdOx1 is a promising vaccine vector that could be used to deliver vaccine antigens where strong cellular immune responses are required for protection.

Original publication

DOI

10.1038/mt.2013.284

Type

Journal article

Journal

Mol Ther

Publication Date

03/2014

Volume

22

Pages

668 - 674

Keywords

Adenoviruses, Simian, Adolescent, Adult, Animals, Antigens, Viral, Dose-Response Relationship, Immunologic, Genetic Vectors, HEK293 Cells, Humans, Influenza A virus, Influenza Vaccines, Middle Aged, Pan troglodytes, RNA-Binding Proteins, Recombinant Proteins, Vaccination, Viral Core Proteins, Viral Matrix Proteins, Virus Replication, Young Adult